Trading under liquidation value and near cash. Any downside is limited here, and they have an easy comp Q2. Also the company is a cheap buyout target at just over $4M and a good balance sheet with no poison pill. Insiders have bought and may continue.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.